TOLREMO THERAPEUTICS
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
TOLREMO THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.tolremo.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
16.1 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Cullgen
Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioMedPartners
BioMedPartners investment in Series A - TOLREMO therapeutics
Altos Ventures
Altos Ventures investment in Series A - TOLREMO therapeutics
BioMedPartners
BioMedPartners investment in Series A - TOLREMO therapeutics
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series A - TOLREMO therapeutics
Redalpine
Redalpine investment in Series A - TOLREMO therapeutics
Newest Events participated
Official Site Inspections
http://www.tolremo.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "TOLREMO therapeutics"
About Us — TOLREMO therapeutics: Stopping Non-genetic …
Wilhelm Krek was one of TOLREMO’s co-founders and was Full Professor of Cell Biology at ETH Zurich since 2003. He was a world leader in cancer cell signaling and had worked at the …See details»
TOLREMO therapeutics - Crunchbase Company Profile & Funding
Sep 20, 2017 TOLREMO therapeutics may be growing as it has successfully completed a significant Series A financing round, securing USD 39 million in investments. This influx of …See details»
TOLREMO therapeutics - LinkedIn
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal ...See details»
TOLRMEO Leadership Gallery — TOLREMO …
Jessica Corson joined Tolremo in 2023 as our Chief Business Officer. Jessica has over 20 years of strategic and operational experience within the biotech industry. Most recently, she was Vice President of Corporate Strategy, …See details»
TOLREMO therapeutics - Funding, Financials, Valuation & Investors
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy. Search Crunchbase. ... How much funding has this …See details»
TOLREMO therapeutics AG - VentureRadar
Nov 5, 2018 TOLREMO develops novel small molecules that eradicate drug resistant cancer cells right at the start of a therapy. TOLREMO’s resistance-breaking add-on therapies can be …See details»
TOLREMO therapeutics AG – Swiss Biotech
TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies. Products, services, technology Proprietary drug discovery and development platform to explore novel …See details»
TOLREMO therapeutics AG - Venturelab
Mar 16, 2017 TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we …See details»
TOLREMO Board of Directors Gallery — TOLREMO therapeutics: …
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by …See details»
TOLREMO therapeutics - Craft
TOLREMO therapeutics has 5 employees at their 1 location and $11.88 m in total funding,. See insights on TOLREMO therapeutics including office locations, competitors, revenue, financials, …See details»
tolremo - redalpine
There is an unmet need for durable therapeutic treatments for cancer patients, as current drugs often lose their effectiveness over time. drug resistance therefore remains a major limiting …See details»
TOLREMO - Products, Competitors, Financials, Employees, …
TOLREMO is a biopharmaceutical company focused on preventing non-genetic cancer drug resistance. The company develops small molecule inhibitors, such as TT125-802, that target …See details»
TOLREMO therapeutics AG - top100startup.ch
Nov 14, 2020 Milestones. 08.05.2024 TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board; 28.11.2023 TOLREMO Treats First Patient in Phase I Trial with TT125-802, a …See details»
Contact Us — TOLREMO therapeutics: Stopping Non-genetic …
At TOLREMO Therapeutics, we’re pioneering therapies that tackle the earliest mechanisms of non-genetic cancer drug resistance. We believe that through collaboration and sharing …See details»
TOLREMO therapeutics - Contacts, Employees, Board Members
Organization. TOLREMO therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. TOLREMO therapeutics has 2 …See details»
Tolremo - Overview, News & Competitors | ZoomInfo.com
TOLREMO therapeutics AG ("TOLREMO") is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering realworld …See details»
News & Events — TOLREMO therapeutics: Stopping Non-genetic …
TOLREMO’s co-founder and CEO Dr. Stefanie Flückiger-Mangual was nominated for the European Lifestars Award - Women-Led Business Leader of the Year. Organized by LSX, the …See details»
TOLREMO therapeutics Company Information - Funding, Investors, …
The company TOLREMO therapeutics has raised a total of $23m in funding over 2 rounds. Key Insights: Seed: $2.6m; Series A: $20.4m; 2025. TOLREMO therapeutics Seed (2017, $2M) …See details»
TOLREMO Scientific Advisory Board Gallery — TOLREMO …
Dr. Alan Sandler is a distinguished leader in oncology and drug development with extensive experience in both industry and academia. His expertise spans clinical development and …See details»